Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

01-01-2015 | Uterine cancer | Book chapter | Article

25. Diagnosis and Management of Stage II Endometrial Cancer

Authors: Rebecca A. Previs, MD, Diane C. Bodurka, MD, MPH

Publisher: Springer India

Login to get access

Abstract

Current staging guidelines define stage II endometrial carcinoma as a tumor that invades the cervical stroma but does not extend beyond the uterus. If the patient is deemed medically operable, surgical management remains the primary treatment modality with the goal of removing all gross disease. Pathologic evaluation of the surgical specimen can help tailor adjuvant chemotherapy. Previously, adjuvant radiation was a mainstay of treatment, but controversies exist about this modality given the lack of data to support improved overall survival. High-risk histologic subtypes (serous, clear cell, carcinosarcoma, high-grade endometrial sarcoma, and leiomyosarcoma) should receive adjuvant chemotherapy with or without tumor-directed radiation.
Literature
1.
Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, et al. Carcinoma of the cervix uteri. J Epidemiol Biostat. 2001;6(1):7–43. PubMed.PubMed
2.
Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer. 1987;60(8 Suppl):2035–41. PubMed.PubMedCrossRef
3.
Onsrud M, Aalders J, Abeler V, Taylor P. Endometrial carcinoma with cervical involvement (stage II): prognostic factors and value of combined radiological-surgical treatment. Gynecol Oncol. 1982;13(1):76–86. PubMed.PubMedCrossRef
4.
Lanciano RM, Curran Jr WJ, Greven KM, Fanning J, Stafford P, Randall ME, et al. Influence of grade, histologic subtype, and timing of radiotherapy on outcome among patients with stage II carcinoma of the endometrium. Gynecol Oncol. 1990;39(3):368–73. PubMed.PubMedCrossRef
5.
Mannel RS, Berman ML, Walker JL, Manetta A, DiSaia PJ. Management of endometrial cancer with suspected cervical involvement. Obstet Gynecol. 1990;75(6):1016–22. PubMed.PubMed
6.
Boente MP, Yordan Jr EL, McIntosh DG, Grendys Jr EC, Orandi YA, Davies S, et al. Prognostic factors and long-term survival in endometrial adenocarcinoma with cervical involvement. Gynecol Oncol. 1993;51(3):316–22. PubMed.PubMedCrossRef
7.
Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet. 2009;105(2):103–4. PubMed.CrossRef
8.
Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynecol Obstet. 2009;105(2):109. PubMed.CrossRef
9.
Resnick KE, Hampel H, Fishel R, Cohn DE. Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol Oncol. 2009;114(1):128–34. PubMed. Pubmed Central PMCID: 2841434.PubMedCentralPubMedCrossRef
10.
Obermair A, Youlden DR, Young JP, Lindor NM, Baron JA, Newcomb P, et al. Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. Int J Cancer (Journal international du cancer). 2010;127(11):2678–84. PubMed. Pubmed Central PMCID: 2947566.CrossRef
11.
Stoffel E, Mukherjee B, Raymond VM, Tayob N, Kastrinos F, Sparr J, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology. 2009;137(5):1621–7. PubMed. Pubmed Central PMCID: 2767441.PubMedCentralPubMedCrossRef
12.
Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer (Journal international du cancer). 1999;81(2):214–8. PubMed.CrossRef
13.
Akin O, Mironov S, Pandit-Taskar N, Hann LE. Imaging of uterine cancer. Radiol Clin North Am. 2007;45(1):167–82. PubMed.PubMedCrossRef
14.
Manfredi R, Mirk P, Maresca G, Margariti PA, Testa A, Zannoni GF, et al. Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. Radiology. 2004;231(2):372–8. PubMed.PubMedCrossRef
15.
Chan JK, Sherman AE, Kapp DS, Zhang R, Osann KE, Maxwell L, et al. Influence of gynecologic oncologists on the survival of patients with endometrial cancer. J Clin Oncol. 2011;29(7):832–8. PubMed.PubMedCrossRef
16.
Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group study LAP2. J Clin Oncol. 2009;27(32):5331–6. PubMed. Pubmed Central PMCID: 2773219.PubMedCentralPubMedCrossRef
17.
Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 study. J Clin Oncol. 2012;30(7):695–700. PubMed. Pubmed Central PMCID: 3295548.PubMedCentralPubMedCrossRef
18.
Kilgore JE, Jackson AL, Ko EM, Soper JT, Van Le L, Gehrig PA, et al. Recurrence-free and 5-year survival following robotic-assisted surgical staging for endometrial carcinoma. Gynecol Oncol. 2013;129(1):49–53. PubMed.PubMedCrossRef
19.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Uterine Neoplasms Version 2.2015. National Comprehensive Network. © 2014. http://​www.​nccn.​org/​professionals/​physician_​gls/​pdf/​uterine.​pdf. Accessed 1 July 2014.
20.
Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet. 2000;355(9213):1404–11. PubMed.PubMedCrossRef
21.
Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(3):744–51. PubMed.PubMedCrossRef
22.
Group AES, Blake P, Swart AM, Orton J, Kitchener H, Whelan T, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009;373(9658):137–46. PubMed. Pubmed Central PMCID: 2646125.CrossRef
23.
Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375(9717):816–23. PubMed.PubMedCrossRef
24.
Creutzberg CL, Nout RA. The role of radiotherapy in endometrial cancer: current evidence and trends. Curr Oncol Rep. 2011;13(6):472–8. PubMed. Pubmed Central PMCID: 3212694.PubMedCentralPubMedCrossRef
25.
Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991;40(1):55–65. PubMed.PubMedCrossRef
26.
Rutledge F. The role of radical hysterectomy in adenocarcinoma of the endometrium. Gynecol Oncol. 1974;2(2–3):331–47. PubMed.PubMedCrossRef
27.
Parsons L, Cesare F. Wertheim hysterectomy in the treatment of endometrial carcinoma. Surg Gynecol Obstet. 1959;108(5):582–90. PubMed.PubMed
28.
Roberts DW. Carcinoma of the body of the uterus at Chelsea Hospital for women, 1943–1953. J Obstet Gynaecol Br Emp. 1961;68:132–8. PubMed.PubMedCrossRef
29.
Watanabe Y, Satou T, Nakai H, Etoh T, Dote K, Fujinami N, et al. Evaluation of parametrial spread in endometrial carcinoma. Obstet Gynecol. 2010;116(5):1027–34. PubMed.PubMedCrossRef
30.
American College of Obstetrics and Gynecology. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol. 2005;106(2):413–25. PubMed.CrossRef
31.
Hernandez E, American College of Obstetricians and Gynecologists. ACOG Practice Bulletin number 65: management of endometrial cancer. Obstet Gynecol. 2006;107(4):952. author reply −3. PubMed.PubMedCrossRef
32.
Pitson G, Colgan T, Levin W, Lockwood G, Manchul L, Milosevic M, et al. Stage II endometrial carcinoma: prognostic factors and risk classification in 170 patients. Int J Radiat Oncol Biol Phys. 2002;53(4):862–7. PubMed.PubMedCrossRef
33.
Horowitz NS, Peters 3rd WA, Smith MR, Drescher CW, Atwood M, Mate TP. Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma. Obstet Gynecol. 2002;99(2):235–40. PubMed.PubMedCrossRef
34.
Rittenberg PV, Lotocki RJ, Heywood MS, Krepart GV. Stage II endometrial carcinoma: limiting post-operative radiotherapy to the vaginal vault in node-negative tumors. Gynecol Oncol. 2005;98(3):434–8. PubMed.PubMedCrossRef
35.
Fanning J. Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy. Gynecol Oncol. 2001;82(2):371–4. PubMed.PubMedCrossRef
36.
Ng TY, Nicklin JL, Perrin LC, Cheuk R, Crandon AJ. Postoperative vaginal vault brachytherapy for node-negative stage II (occult) endometrial carcinoma. Gynecol Oncol. 2001;81(2):193–5. PubMed.PubMedCrossRef
37.
Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol. 1998;29(6):551–8. PubMed.PubMedCrossRef
38.
Mendivil A, Schuler KM, Gehrig PA. Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control. 2009;16(1):46–52. PubMed.PubMed
39.
Sutton G, Axelrod JH, Bundy BN, Roy T, Homesley H, Lee RB, et al. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006;100(2):349–54. PubMed.PubMedCrossRef
40.
Fader AN, Boruta D, Olawaiye AB, Gehrig PA. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol. 2010;22(1):21–9. PubMed.PubMedCrossRef
41.
Boruta 2nd DM, Gehrig PA, Fader AN, Olawaiye AB. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;115(1):142–53. PubMed.PubMedCrossRef
42.
Einstein MH, Frimer M, Kuo DY, Reimers LL, Mehta K, Mutyala S, et al. Phase II trial of adjuvant pelvic radiation “sandwiched” between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma. Gynecol Oncol. 2012;124(1):21–5. PubMed. Pubmed Central PMCID: 3681611.PubMedCentralPubMedCrossRef
43.
Sutton G, Kauderer J, Carson LF, Lentz SS, Whitney CW, Gallion H, et al. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 2005;96(3):630–4. PubMed.PubMedCrossRef
44.
Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group study. J Clin Oncol. 2007;25(5):526–31. PubMed.PubMedCrossRef
45.
Cantrell LA, Havrilesky L, Moore DT, O’Malley D, Liotta M, Secord AA, et al. A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. Gynecol Oncol. 2012;127(1):22–6. PubMed.PubMedCrossRef
46.
Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, Degeest K, et al. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol. 2010;28(16):2727–31. PubMed. Pubmed Central PMCID: 2881851.PubMedCentralPubMedCrossRef
47.
Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I–IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007;107(2):177–85. PubMed. Pubmed Central PMCID: 2752331.PubMedCentralPubMedCrossRef
48.
Wolfson AHBM, Rocereto TF, Mannel RS, Lee Y-C, Futoran R, Cohn D, Ioffe OB. A Gynecologic Oncology Group randomized trial of whole abdominal irradiation versus chemotherapy in optimally debulked carcinosarcomas of the uterus. Int J Gynecol Cancer. 2006;16(3):45.
49.
Wong L, See HT, Khoo-Tan HS, Low JS, Ng WT, Low JJ. Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed mullerian tumors of the uterus. Int J Gynecol Cancer. 2006;16(3):1364–9. PubMed.PubMedCrossRef
50.
Menczer J, Levy T, Piura B, Chetrit A, Altaras M, Meirovitz M, et al. A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol. 2005;97(1):166–70. PubMed.PubMedCrossRef
51.
Manolitsas TP, Wain GV, Williams KE, Freidlander M, Hacker NF. Multimodality therapy for patients with clinical stage I and II malignant mixed Mullerian tumors of the uterus. Cancer. 2001;91(8):1437–43. PubMed.PubMedCrossRef
52.
Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer. 2006;95(3):266–71. PubMed. Pubmed Central PMCID: 2360651.PubMedCentralPubMedCrossRef
53.
Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2008;108(1):226–33. PubMed.PubMedCrossRef
54.
Kuoppala T, Maenpaa J, Tomas E, Puistola U, Salmi T, Grenman S, et al. Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy. Gynecol Oncol. 2008;110(2):190–5. PubMed.PubMedCrossRef
55.
Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–results from two randomised studies. Eur J Cancer. 2010;46(13):2422–31. PubMed. Pubmed Central PMCID: 3552301.PubMedCentralPubMedCrossRef
56.
DiSaia PJ, Gynecologic Oncology Group. Pelvic radiation therapy or vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with high-risk stage I or stage II endometrial cancer. https://​clinicaltrials.​gov/​ct2/​show/​NCT00807768. Accessed 1 July 2014.
57.
Creutzberg CL. Randomized trial of radiation therapy with or without chemotherapy for endometrial cancer (PORTEC-3). https://​clinicaltrials.​gov/​ct2/​show/​NCT00411138. Accessed 1 July 2014.
58.
Edge SB, American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. xiv, 648.
59.
Shah JP, Bryant CS, Kumar S, Ali-Fehmi R, Malone Jr JM, Morris RT. Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma. Obstet Gynecol. 2008;112(5):1102–8. PubMed.PubMedCrossRef
60.
Barney B, Tward JD, Skidmore T, Gaffney DK. Does radiotherapy or lymphadenectomy improve survival in endometrial stromal sarcoma? Int J Gynecol Cancer. 2009;19(7):1232–8. PubMed.PubMedCrossRef
61.
Group EESNW. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii92–9. PubMed.
62.
Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. Clinical management of uterine sarcomas. Lancet Oncol. 2009;10(12):1188–98. PubMed.PubMedCrossRef
63.
Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis Jr JL. Treatment of endometrial stromal tumors. Gynecol Oncol. 1990;36(1):60–5. PubMed.PubMedCrossRef
64.
Weitmann HD, Knocke TH, Kucera H, Potter R. Radiation therapy in the treatment of endometrial stromal sarcoma. Int J Radiat Oncol Biol Phys. 2001;49(3):739–48. PubMed.PubMedCrossRef
65.
Reed NS, Mangioni C, Malmstrom H, Scarfone G, Poveda A, Pecorelli S, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group study (protocol 55874). Eur J Cancer. 2008;44(6):808–18. PubMed.PubMedCrossRef
66.
Ricci S, Giuntoli 2nd RL, Eisenhauer E, Lopez MA, Krill L, Tanner 3rd EJ, et al. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma? Gynecol Oncol. 2013;131(3):629–33. PubMed.PubMedCrossRef
67.
Hensley, M, Gynecologic Oncology Group. Gemcitabine hydrochloride and docetaxel followed by doxorubicin hydrochloride or observation in treating patients with high-risk uterine leiomyosarcoma previously removed by surgery. https://​clinicaltrials.​gov/​ct2/​show/​NCT01533207. Accesssed 1 July 2014.
68.
Novetsky AP, Powell MA. Management of sarcomas of the uterus. Curr Opin Oncol. 2013;25(5):546–52. PubMed.PubMedCrossRef